Table 1.

fMRI BOLD response for idalopirdine compared to vehicle following a single administration.

Vehicle vs. Idalopiridine, postive BOLD volume of activation
15–25 min post-treatment				25–35 min post-treatment				35–45 min post-treatment
Brain area	Veh	I	P-val	Brain area	Veh	I	P-val	Brain area	Veh	I	P-val
Reuniens nucleus	0	2	0.073	Ventral pallidum	0	5	0.022	Ventral pallidum	0	8	0.006
Ventral pallidum	0	3	0.073	Magnocellular preoptic nucleus	0	1	0.026	Accumbens shell	0	10	0.008
Magnocellular preoptic nucleus	0	0	0.082	Secondary somatosensory ctx	4	32	0.056	Diagonal band of Broca	0	7	0.008
Medial pretectal area	0	0	0.082	Accumbens shell	0	6	0.069	Medial preoptic area	1	8	0.013
Substantia innominata	0	0	0.082	Diagonal band of Broca	0	4	0.092	Infralimbic ctx	0	14	0.015
Accumbens shell	0	4	0.102	Caudal piriform ctx	0	23	0.097	Substantia nigra reticularis	6	17	0.033
Medial septum	0	0	0.114	Supramammillary nucleus	0	1	0.111	Periaqueductal gray thalamus	24	47	0.037
Lateral preoptic area	0	3	0.137	Inferior colliculus	62	85	0.121	Magnocellular preoptic nucleus	0	1	0.042

Shown are three sets of results each representing comparisons between vehicle (Veh, n = 9) and idalopirdine (I, n = 10) treatment groups at times 15–25 (left), 25–35 (middle), and 35–45 (right) min post treatment. The probability values presented on the far-right column were derived using a Kruskall-Wallis test statistic. Lists were generated to include all areas (out of a total list of 171 areas that comprise the rat MRI atlas) that differed significantly (p < 0.05) for the epoch in which we observed the most changes (i.e., the 35–45 min epoch). Areas are rank-ordered by p-value for visualization. Areas highlighted in bold differed significantly between treatment groups. Areas listed in gray show areas that come closest to threshold for statistical significance.